Cargando…

Dienogest alone or dienogest combined with estrogens in the treatment of ovarian endometriomas, that is the question. A retrospective cohort study

PURPOSE: to compare the effects of Dienogest 2 mg (D) alone or combined with estrogens (D + ethinylestradiol 0.03 mg, D + EE; D + estradiol valerate 1–3 mg, D + EV) in terms of symptoms and endometriotic lesions variations. METHODS: This retrospective study included symptomatic patients in reproduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Forno, Simona, Orsini, Benedetta, Verrelli, Ludovica, Caroli, Martina, Aru, Anna Chiara, Lenzi, Jacopo, Raimondo, Diego, Arena, Alessandro, Borghese, Giulia, Paradisi, Roberto, Meriggiola, Maria Cristina, Seracchioli, Renato, Casadio, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435622/
https://www.ncbi.nlm.nih.gov/pubmed/37433947
http://dx.doi.org/10.1007/s00404-023-07125-2
_version_ 1785092143574941696
author Del Forno, Simona
Orsini, Benedetta
Verrelli, Ludovica
Caroli, Martina
Aru, Anna Chiara
Lenzi, Jacopo
Raimondo, Diego
Arena, Alessandro
Borghese, Giulia
Paradisi, Roberto
Meriggiola, Maria Cristina
Seracchioli, Renato
Casadio, Paolo
author_facet Del Forno, Simona
Orsini, Benedetta
Verrelli, Ludovica
Caroli, Martina
Aru, Anna Chiara
Lenzi, Jacopo
Raimondo, Diego
Arena, Alessandro
Borghese, Giulia
Paradisi, Roberto
Meriggiola, Maria Cristina
Seracchioli, Renato
Casadio, Paolo
author_sort Del Forno, Simona
collection PubMed
description PURPOSE: to compare the effects of Dienogest 2 mg (D) alone or combined with estrogens (D + ethinylestradiol 0.03 mg, D + EE; D + estradiol valerate 1–3 mg, D + EV) in terms of symptoms and endometriotic lesions variations. METHODS: This retrospective study included symptomatic patients in reproductive age with ultrasound diagnosis of ovarian endometriomas. Medical therapy for at least 12 months with D, D + EE or D + EV was required. Women were evaluated at baseline visit (V1) and after 6 (V2) and 12 months (V3) of therapy. RESULTS: 297 patients were enrolled (156 in the D group, 58 in the D + EE group, 83 in the D + EV group). Medical treatment leaded to a significant reduction in size of endometriomas after 12 months, with no differences between the three groups. When comparing D and D + EE/D + EV groups, a significant decrease of dysmenorrhea was detected in the D group than in D + EE/D + EV group. Conversely, the reduction of dysuria was more significative in the D + EE/D + EV groups rather than in the D group. Regarding tolerability, treatment associated side effects were reported by 16.2% patients. The most frequent one was uterine bleeding/spotting, significantly higher in the D + EV group. CONCLUSION: Dienogest alone or associated with estrogens (EE/EV) seems to be equally effective in reducing endometriotic lesions mean diameter. The reduction of dysmenorrhea was more significative when D was administered alone, while dysuria seems to improve more when D is associated with estrogens. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00404-023-07125-2.
format Online
Article
Text
id pubmed-10435622
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-104356222023-08-19 Dienogest alone or dienogest combined with estrogens in the treatment of ovarian endometriomas, that is the question. A retrospective cohort study Del Forno, Simona Orsini, Benedetta Verrelli, Ludovica Caroli, Martina Aru, Anna Chiara Lenzi, Jacopo Raimondo, Diego Arena, Alessandro Borghese, Giulia Paradisi, Roberto Meriggiola, Maria Cristina Seracchioli, Renato Casadio, Paolo Arch Gynecol Obstet General Gynecology PURPOSE: to compare the effects of Dienogest 2 mg (D) alone or combined with estrogens (D + ethinylestradiol 0.03 mg, D + EE; D + estradiol valerate 1–3 mg, D + EV) in terms of symptoms and endometriotic lesions variations. METHODS: This retrospective study included symptomatic patients in reproductive age with ultrasound diagnosis of ovarian endometriomas. Medical therapy for at least 12 months with D, D + EE or D + EV was required. Women were evaluated at baseline visit (V1) and after 6 (V2) and 12 months (V3) of therapy. RESULTS: 297 patients were enrolled (156 in the D group, 58 in the D + EE group, 83 in the D + EV group). Medical treatment leaded to a significant reduction in size of endometriomas after 12 months, with no differences between the three groups. When comparing D and D + EE/D + EV groups, a significant decrease of dysmenorrhea was detected in the D group than in D + EE/D + EV group. Conversely, the reduction of dysuria was more significative in the D + EE/D + EV groups rather than in the D group. Regarding tolerability, treatment associated side effects were reported by 16.2% patients. The most frequent one was uterine bleeding/spotting, significantly higher in the D + EV group. CONCLUSION: Dienogest alone or associated with estrogens (EE/EV) seems to be equally effective in reducing endometriotic lesions mean diameter. The reduction of dysmenorrhea was more significative when D was administered alone, while dysuria seems to improve more when D is associated with estrogens. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00404-023-07125-2. Springer Berlin Heidelberg 2023-07-12 2023 /pmc/articles/PMC10435622/ /pubmed/37433947 http://dx.doi.org/10.1007/s00404-023-07125-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle General Gynecology
Del Forno, Simona
Orsini, Benedetta
Verrelli, Ludovica
Caroli, Martina
Aru, Anna Chiara
Lenzi, Jacopo
Raimondo, Diego
Arena, Alessandro
Borghese, Giulia
Paradisi, Roberto
Meriggiola, Maria Cristina
Seracchioli, Renato
Casadio, Paolo
Dienogest alone or dienogest combined with estrogens in the treatment of ovarian endometriomas, that is the question. A retrospective cohort study
title Dienogest alone or dienogest combined with estrogens in the treatment of ovarian endometriomas, that is the question. A retrospective cohort study
title_full Dienogest alone or dienogest combined with estrogens in the treatment of ovarian endometriomas, that is the question. A retrospective cohort study
title_fullStr Dienogest alone or dienogest combined with estrogens in the treatment of ovarian endometriomas, that is the question. A retrospective cohort study
title_full_unstemmed Dienogest alone or dienogest combined with estrogens in the treatment of ovarian endometriomas, that is the question. A retrospective cohort study
title_short Dienogest alone or dienogest combined with estrogens in the treatment of ovarian endometriomas, that is the question. A retrospective cohort study
title_sort dienogest alone or dienogest combined with estrogens in the treatment of ovarian endometriomas, that is the question. a retrospective cohort study
topic General Gynecology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435622/
https://www.ncbi.nlm.nih.gov/pubmed/37433947
http://dx.doi.org/10.1007/s00404-023-07125-2
work_keys_str_mv AT delfornosimona dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT orsinibenedetta dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT verrelliludovica dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT carolimartina dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT aruannachiara dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT lenzijacopo dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT raimondodiego dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT arenaalessandro dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT borghesegiulia dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT paradisiroberto dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT meriggiolamariacristina dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT seracchiolirenato dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy
AT casadiopaolo dienogestaloneordienogestcombinedwithestrogensinthetreatmentofovarianendometriomasthatisthequestionaretrospectivecohortstudy